Progress Or Hype? A Decade Of Cell Therapy In Japan

Mixed Commercial Success

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

After ten years of promising investment for cell therapy, Japan has cautiously reviewing its policies.
commercial cell therapy success elusive in Japan despite supportive policies • Source: Shutterstock

More from Japan

More from Focus On Asia